wet age-related macular degeneration
Conditions
Interventions
Eylea (aflibercept)
Beovu(brolucizmab)
Sponsors
kagawa univercity
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) BCVA: 0.1-1.0 2) AMD with subfoveal fluid on fluorescent angiography, indocyanine green angiography and/or optical coherence tomography 3) Willingness to provide written informed consent 4) outpatient
Exclusion criteria
Exclusion criteria: 1) Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas 2) Presence of subretinal hemorrhage, scar or macular fibrosis (>50% lesion area) 3) Prior treatment with anti-VEGF drug, photodynamic therapy 4) Prior treatment with dexamethasone (<6 months) or triamcinolone (<30 days), intraocular surgery (<3 months) 5) Active intraocular inflammation 6) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 7) Patient who the doctor in charge judges are ineligible for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of change in visual acuity at 52 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| The average treatment number according to the medicine , central macular thickness, change of leakage in retinal region, leakage from a polyp, leakage from choroidal neovascularization, subretinal fluid , the rate of incident and the enlargement of the geographic atrophy | — |
Countries
Japan
Contacts
Public Contactyukiko miyoshi
kagawa university hospital Ophthalmology
Outcome results
None listed